<DOC>
	<DOCNO>NCT01908894</DOCNO>
	<brief_summary>The primary objective ass speed absorption BIOD-123 BIOD-125 compare Humalog .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Properties BIOD-123 BIOD-125 Compared Humalog® Subjects With Type 1 Diabetes Including Assessments Injection Site Toleration</brief_title>
	<detailed_description>The primary objective ass speed absorption BIOD-123 BIOD-125 compare Humalog . The secondary objective assess pharmacokinetic characteristic BIOD-123 BIOD-125 compare Humalog® , assess pharmacodynamic characteristic BIOD-123 BIOD-125 compare Humalog® , evaluate safety tolerability BIOD-123 BIOD-125 compare Humalog®</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1 . Age : ≥18 ≤70 year 2 . BMI : ≥18 ≤30 kg/m2 3 . Diagnosed type 1 diabetes mellitus least 1 year 4 . Insulin antibody ≤10 μU/mL screen 1 . Type 2 diabetes mellitus 2 . History &gt; 2 severe hypoglycemic event within 3 month prior screen 3 . Serum Cpeptide &gt; 1.0 ng/mL 4 . Hemoglobin A1c ( HbA1c ) &gt; 10.0 % 5 . Females breast feeding , pregnant , intend become pregnant study 6 . A sexually active person use adequate contraceptive method 7 . Positive serology human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C 8 . Abnormal ECG , safety lab , physical examination result deem clinically significant investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>